Advertisement

Impfen bei Immundefizienz

Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen.(II) Impfen bei 1. Primären Immundefekterkrankungen und 2. HIV-Infektion
Bekanntmachungen – Amtliche Mitteilungen
  • 226 Downloads

Literatur

  1. 1.
    Reda SM, Cant AJ (2015) The importance of vaccination and immunoglobulin treatment for patients with primary immunodeficiency diseases (PIDs)–World PI Week April 22–29, 2015. Eur J Immunol 45(5):1285–1286PubMedCrossRefGoogle Scholar
  2. 2.
    Sarmiento JD, Villada F, Orrego JC, Franco JL, Trujillo-Vargas CM (2016) Adverse events following immunization in patients with primary immunodeficiencies. Vaccine 34(13):1611–1616PubMedCrossRefGoogle Scholar
  3. 3.
    Niehues T, Bogdan C, Hecht J, Mertens T, Wiese-Posselt M, Zepp F (2017) Impfen bei Immundefizienz : Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen(I) Grundlagenpapier. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 60(6):674–684PubMedCrossRefGoogle Scholar
  4. 4.
    Medical Advisory Committee of the Immune Deficiency F, Shearer WT, Fleisher TA, Buckley RH, Ballas Z, Ballow M et al (2014) Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol 133(4):961–966CrossRefGoogle Scholar
  5. 5.
    Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M et al (2014) 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58(3):309–18, e44–100PubMedCrossRefGoogle Scholar
  6. 6.
    Picard C, Gaspar BH, Al-Herz W, Bousfiha A, Casanova JL, Chatila T et al (2018) International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol 38(1):96–128PubMedCrossRefGoogle Scholar
  7. 7.
    Goldacker S, Draeger R, Warnatz K, Huzly D, Salzer U, Thiel J et al (2007) Active vaccination in patients with common variable immunodeficiency (CVID). Clin Immunol 124(3):294–303PubMedCrossRefGoogle Scholar
  8. 8.
    Robert Koch-Institut (2018) Empfehlungen der Ständigen Impfkommission (STIKO) am RKI – 2018/2019. Epidemiologisches Bulletin, 34/2018Google Scholar
  9. 9.
    Seidel MG, Grohmann E, Sadeghi K, Pollak A, Heitger A, Forster-Waldl E (2010) Vaccination against tick-borne encephalitis virus tests specific IgG production ability in patients under immunoglobulin substitution therapy. Vaccine 28(40):6621–6626PubMedCrossRefGoogle Scholar
  10. 10.
    Chinn IK, Shearer WT (2015) Severe combined immunodeficiency disorders. Immunol Allergy Clin North Am 35(4):671–694PubMedCrossRefGoogle Scholar
  11. 11.
    Al-Sukaiti N, Reid B, Lavi S, Al-Zaharani D, Atkinson A, Roifman CM et al (2010) Safety and efficacy of measles, mumps, and rubella vaccine in patients with DiGeorge syndrome. J Allergy Clin Immunol 126(4):868–869PubMedCrossRefGoogle Scholar
  12. 12.
    Perez EE, Bokszczanin A, McDonald-McGinn D, Zackai EH, Sullivan KE (2003) Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Pediatrics 112(4):e325PubMedCrossRefGoogle Scholar
  13. 13.
    Beck CR, McKenzie BC, Hashim AB, Harris RC, Zanuzdana A, Agboado G et al (2013) Influenza vaccination for immunocompromised patients: summary of a systematic review and meta-analysis. Influenza Other Respir Viruses 7(Suppl 2):72–75PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Hanitsch LG, Lobel M, Mieves JF, Bauer S, Babel N, Schweiger B et al (2016) Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency. Vaccine 34(21):2417–2423PubMedCrossRefGoogle Scholar
  15. 15.
    Chertow DS, Memoli MJ (2013) Bacterial coinfection in influenza: a grand rounds review. JAMA 309(3):275–282PubMedCrossRefGoogle Scholar
  16. 16.
    de Beaucoudrey L, Samarina A, Bustamante J, Cobat A, Boisson-Dupuis S, Feinberg J et al (2010) Revisiting human IL-12Rbeta1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) 89(6):381–402CrossRefGoogle Scholar
  17. 17.
    Hambleton S, Goodbourn S, Young DF, Dickinson P, Mohamad SM, Valappil M et al (2013) STAT2 deficiency and susceptibility to viral illness in humans. Proc Natl Acad Sci U S A 110(8):3053–3058PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Toubiana J, Okada S, Hiller J, Oleastro M, Lagos Gomez M, Aldave Becerra JC et al (2016) Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood 127(25):3154–3164PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Picard C, von Bernuth H, Ghandil P, Chrabieh M, Levy O, Arkwright PD et al (2010) Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore) 89(6):403–425CrossRefGoogle Scholar
  20. 20.
    McKelvie B, Top K, McCusker C, Letenyi D, Issekutz TB, Issekutz AC (2014) Fatal pneumococcal meningitis in a 7-year-old girl with interleukin-1 receptor activated kinase deficiency (IRAK-4) despite prophylactic antibiotic and IgG responses to Streptococcus pneumoniae vaccines. J Clin Immunol 34(3):267–271PubMedCrossRefGoogle Scholar
  21. 21.
    Walter ND, Taylor TH, Shay DK, Thompson WW, Brammer L, Dowell SF et al (2010) Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. Clin Infect Dis 50(2):175–183PubMedCrossRefGoogle Scholar
  22. 22.
    Baxter R, Keshavan P, Welsch JA, Han L, Smolenov I (2016) Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants. Hum Vaccine Immunother 12(5):1300–1310CrossRefGoogle Scholar
  23. 23.
    Ghannam A, Pernollet M, Fauquert JL, Monnier N, Ponard D, Villiers MB et al (2008) Human C3 deficiency associated with impairments in dendritic cell differentiation, memory B cells, and regulatory T cells. J Immunol 181(7):5158–5166PubMedCrossRefGoogle Scholar
  24. 24.
    Arbore G, West EE, Spolski R, Robertson AAB, Klos A, Rheinheimer C et al (2016) T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4(+) T cells. Science 352(6292):aad1210PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE (2008) Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5–49 years of age. Vaccine 26(38):4940–4946PubMedCrossRefGoogle Scholar
  26. 26.
    Salzman MB, Sharrar RG, Steinberg S, LaRussa P (1997) Transmission of varicella-vaccine virus from a healthy 12-month-old child to his pregnant mother. J Pediatr 131(1 Pt 1):151–154PubMedCrossRefGoogle Scholar
  27. 27.
    Shearer WT, Fleisher TA, Buckley RH, Ballas Z, Ballow M, Blaese RM (2014) Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol 133(4):961–966PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Wiedermann U, Sitte H, al Burgmann H (2016) Impfungen bei Immundefekten/Immunsuppression – Expertenstatus und Empfehlungen. Klin Wochenschr 128(Suppl 4):337–376CrossRefGoogle Scholar
  29. 29.
    Gelderblom WC, Cawood ME, Snyman SD, Vleggaar R, Marasas WF (1993) Structure-activity relationships of fumonisins in short-term carcinogenesis and cytotoxicity assays. Food Chem Toxicol 31(6):407–414PubMedCrossRefGoogle Scholar
  30. 30.
    Titanji K, De Milito A, Cagigi A, Thorstensson R, Grutzmeier S, Atlas A et al (2006) Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 108(5):1580–1587PubMedCrossRefGoogle Scholar
  31. 31.
    Kim ES, Ackermann C, Toth I, Dierks P, Eberhard JM, Wroblewski R et al (2017) Down-regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progression. J Leukoc Biol 101(5):1263–1271PubMedCrossRefGoogle Scholar
  32. 32.
    Hu Z, Luo Z, Wan Z, Wu H, Li W, Zhang T et al (2015) HIV-associated memory B cell perturbations. Vaccine 33(22):2524–2529PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    From the Centers for Disease Control and Prevention (1993) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 269(6):729–730CrossRefGoogle Scholar
  34. 34.
    Glesby MJ (1998) Immunizations during HIV infection. Curr Opin Infect Dis 11(1):17–21PubMedCrossRefGoogle Scholar
  35. 35.
    Modjarrad K, Vermund SH (2010) Effect of treating co-infections on HIV-1 viral load: a systematic review. Lancet Infect Dis 10(7):455–463PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Crum-Cianflone NF, Wallace MR (2014) Vaccination in HIV-infected adults. Aids Patient Care Stds 28(8):397–410PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Association CsH (2015) Immunization guideines of HIV infected children. https://www.chiva.org.uk/guidelines/immunisation/ . Zugegriffen: 19. Juni 2018 Google Scholar
  38. 38.
    Menson EN, Mellado MJ, Bamford A, Castelli G, Duiculescu D, Marczynska M et al (2012) Guidance on vaccination of HIV-infected children in Europe. HIV Med 13(6):333–336, e1–14PubMedCrossRefGoogle Scholar
  39. 39.
    Revised surveillance case definition for HIV infection—United States, 2014. MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports. 2014;63(Rr-03):1–10 Google Scholar
  40. 40.
    Laserson KF, Nyakundi D, Feikin DR, Nyambane G, Cook E, Oyieko J et al (2012) Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq((R)), in Kenya, including among HIV-infected and HIV-exposed infants. Vaccine 30(Suppl 1):A61–A70PubMedCrossRefGoogle Scholar
  41. 41.
    Levin MJ, Lindsey JC, Kaplan SS, Schimana W, Lawrence J, McNeal MM et al (2017) Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. AIDS 31(1):49–59PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Bekker V, Scherpbier H, Pajkrt D, Jurriaans S, Zaaijer H, Kuijpers TW (2006) Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. Pediatrics 118(2):e315–e322PubMedCrossRefGoogle Scholar
  43. 43.
    Ghosh S, Feyen O, Jebran AF, Huck K, Jetzek-Zader M, Bas M et al (2009) Memory B cell function in HIV-infected children-decreased memory B cells despite ART. Pediatr Res 66(2):185–190PubMedCrossRefGoogle Scholar
  44. 44.
    Geretti AM, Brook G, Cameron C, Chadwick D, French N, Heyderman R et al (2016) British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015. HIV Med 17(Suppl 3):S2–S81PubMedCrossRefGoogle Scholar
  45. 45.
    Abzug MJ, Song LY, Fenton T, Nachman SA, Levin MJ, Rosenblatt HM (2007) Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. Pediatrics 120(5):e1190–e1202PubMedCrossRefGoogle Scholar
  46. 46.
    Robert Koch-Institut (2018) Empfehlungen der Ständigen Impfkommission (STIKO) am RKI 2018/2019. Epidemiologisches Bulletin, 34/2018Google Scholar
  47. 47.
    Ida S, Tachikawa N, Nakajima A, Daikoku M, Yano M, Kikuchi Y et al (2002) Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection. Clin Infect Dis 34(3):379–385PubMedCrossRefGoogle Scholar
  48. 48.
    Kourkounti S, Papaizos V, Leuow K, Kordosis T, Antoniou C (2013) Hepatitis A vaccination and immunological parameters in HIV-infected patients. Viral Immunol 26(5):357–363PubMedCrossRefGoogle Scholar
  49. 49.
    Mena G, Garcia-Basteiro AL, Bayas JM (2015) Hepatitis B and A vaccination in HIV-infected adults: A review. Hum Vaccin Immunother 11(11):2582–2598PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Kourkounti S, Mavrianou N, Paparizos VA, Kyriakis K, Hatzivassiliou M, Kordosis T et al (2012) Immune response to hepatitis A vaccination in HIV-infected men in Greece. Int J Std Aids 23(7):464–467PubMedCrossRefGoogle Scholar
  51. 51.
    Tseng YT, Chang SY, Liu WC, Sun HY, Wu CH, Wu PY et al (2013) Comparative effectiveness of two doses versus three doses of hepatitis A vaccine in human immunodeficiency virus-infected and -uninfected men who have sex with men. Hepatology 57(5):1734–1741PubMedCrossRefGoogle Scholar
  52. 52.
    Kerneis S, Desaint C, Brichler S, Rey D, Belarbi L, Gordien E et al (2011) Long-term persistence of humoral immunity after hepatitis A vaccination in HIV-infected adults. J Acquir Immune Defic Syndr 57(3):e63–6PubMedCrossRefGoogle Scholar
  53. 53.
    Launay O, Grabar S, Gordien E, Desaint C, Jegou D, Abad S et al (2008) Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J Acquir Immune Defic Syndr 49(3):272–275PubMedCrossRefGoogle Scholar
  54. 54.
    Lin KL et al (2017) Effectiveness of HAV vaccination among HIV-positive patients during an acute hepatitis A outbreak. Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, S abstract 582Google Scholar
  55. 55.
    Jablonowska E, Kuydowicz J (2014) Durability of response to vaccination against viral hepatitis A in HIV-infected patients: a 5-year observation. Int J Std Aids 25(10):745–750PubMedCrossRefGoogle Scholar
  56. 56.
    Robert Koch-Institut (2015) RKI-Ratgeber Hepatitis A. http://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_HepatitisA.html#doc2374552bodyText14 . Zugegriffen: 19. Juni 2018 Google Scholar
  57. 57.
    Robert Koch-Institut (2013) Ständige Impfkommission am RKI: Wissenschaftliche Begründung für die Änderung der Empfehlung zur Impfung gegen Hepatitis B. Epidemiologisches Bulletin 36/37 2013Google Scholar
  58. 58.
    van den Berg R, van Hoogstraten I, van Agtmael M (2009) Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions. AIDS Rev 11(3):157–164PubMedGoogle Scholar
  59. 59.
    Catherine FX, Piroth L (2017) Hepatitis B virus vaccination in HIV-infected people: a review. Hum Vaccin Immunother 13(6):1–10PubMedCrossRefGoogle Scholar
  60. 60.
    de Silva TI, Green ST, Cole J, Stone BJ, Dockrell DH, Vedio AB (2014) Successful use of Fendrix in HIV-infected non-responders to standard hepatitis B vaccines. J Infect 68(4):397–399PubMedCrossRefGoogle Scholar
  61. 61.
    Alon D, Stein GY, Hadas-Golan V, Tau L, Brosh T, Turner D (2017) Immunogenicity of sci-B-Vac (a third-generation hepatitis B vaccine) in HIV-positive adults. Isr Med Assoc J 19(3):143–146PubMedGoogle Scholar
  62. 62.
    Roggendorf H (2015) Non-Responder nach Hepatitis B-Impfung: Problemlösung ist in Reichweite. Dtsch Arztebl 112/2015:C1281Google Scholar
  63. 63.
    Shouval D, Roggendorf H, Roggendorf M (2015) Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine. Med Microbiol Immunol 204(1):57–68PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Giacomet V et al (2017) Immunological responses after a booster dose of HBV vaccine in HIV-infected youth. Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, S abstract. 2017Google Scholar
  65. 65.
    Flynn PM, Cunningham CK, Rudy B, Wilson CM, Kapogiannis B, Worrell C et al (2011) Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens. J Acquir Immune Defic Syndr 56(4):325–332PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Bakker M, Bunge EM, Marano C, de Ridder M, De Moerlooze L (2016) Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review. Expert Rev Vaccines 15(7):829–851PubMedCrossRefGoogle Scholar
  67. 67.
    Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J et al (2016) Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med 375(11):1019–1032PubMedCrossRefGoogle Scholar
  68. 68.
    Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ et al (2015) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372(22):2087–2096PubMedCrossRefGoogle Scholar
  69. 69.
    Berkowitz EM, Moyle G, Stellbrink HJ, Schurmann D, Kegg S, Stoll M et al (2015) Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis 211(8):1279–1287PubMedCrossRefGoogle Scholar
  70. 70.
    Siedler A, Koch J, Ultsch B et al (2017) Background paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany. Statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute (RKI). Bundesgesundheitsblatt 60:1162–1179CrossRefGoogle Scholar
  71. 71.
    Konopnicki D, Manigart Y, Gilles C, Barlow P, De Marchin J, Feoli F et al (2016) High-risk human papillomavirus genotypes distribution in a cohort of HIV-positive women living in Europe: epidemiological implication for vaccination against human papillomavirus. AIDS 30(3):425–433PubMedGoogle Scholar
  72. 72.
    Patel P, Bush T, Conley L et al (2017) Prevalence, clearance, and incidence of human papillomavirus (HPV) types covered by current vaccines in HIV-Iinfected men in the SUN study. Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, S abstract 597Google Scholar
  73. 73.
    Meites E, Gorbach PM, Gratzer B, Panicker G, Steinau M, Collins T et al (2016) Monitoring for Human Papillomavirus Vaccine Impact Among Gay, Bisexual, and Other Men Who Have Sex With Men-United States, 2012–2014. J Infect Dis 214(5):689–696PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Kreuter A, Potthoff A, Brockmeyer NH, Gambichler T, Swoboda J, Stucker M et al (2010) Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany. Br J Dermatol 162(6):1269–1277PubMedCrossRefGoogle Scholar
  75. 75.
    Piketty C, Selinger-Leneman H, Bouvier AM, Belot A, Mary-Krause M, Duvivier C et al (2012) Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV. J Clin Oncol 30(35):4360–4366PubMedCrossRefGoogle Scholar
  76. 76.
    Committee Opinion No. 704 Summary: Human Papillomavirus Vaccination. Obstet Gynecol. 2017;129(6):1155–6. Google Scholar
  77. 77.
    Kojic EM, Kang M, Cespedes MS, Umbleja T, Godfrey C, Allen RT et al (2014) Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis 59(1):127–135PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Lin A, Ong KJ, Hobbelen P, King E, Mesher D, Edmunds WJ et al (2017) Impact and cost-effectiveness of selective human papillomavirus vaccination of men who have sex with men. Clin Infect Dis 64(5):580–588PubMedGoogle Scholar
  79. 79.
    Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM et al (2010) Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 202(8):1246–1253PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J et al (2015) A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372(8):711–723PubMedCrossRefGoogle Scholar
  81. 81.
    Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr., Aranda C, Jessen H et al (2011) HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 365(17):1576–1585PubMedCrossRefGoogle Scholar
  82. 82.
    AG Influenza der Ständigen Impfkommission (STIKO) (2018) Wissenschaftliche Begründung für die Empfehlung des quadrivalenten saisonalen Influenza-impfstoffs. Epid Bull 2:19–28  https://doi.org/10.17886/EpiBull-2018-002
  83. 83.
    Remschmidt C, Wichmann O, Harder T (2014) Influenza vaccination in HIV-infected individuals: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety. Vaccine 32(43):5585–5592PubMedCrossRefGoogle Scholar
  84. 84.
    Lau YF, Tang LH, Chien Lye D, Ooi EE, Leo YS (2017) Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore. Hum Vaccin Immunother 13(3):551–560PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Simmons RD, Kirwan P, Beebeejaun K, Riordan A, Borrow R, Ramsay ME et al (2015) Risk of invasive meningococcal disease in children and adults with HIV in England: a population-based cohort study. BMC Med 13:297PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Miller L, Arakaki L, Ramautar A, Bodach S, Braunstein SL, Kennedy J et al (2014) Elevated risk for invasive meningococcal disease among persons with HIV. Ann Intern Med 160(1):30–37PubMedCrossRefGoogle Scholar
  87. 87.
    Cohen C, Singh E, Wu HM, Martin S, de Gouveia L, Klugman KP et al (2010) Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa. AIDS 24(9):1351–1360PubMedCrossRefGoogle Scholar
  88. 88.
    Blackwell CW (2017) Meningococcal vaccination in men who have sex with men. Public Health Nurs 34(2):147–151PubMedCrossRefGoogle Scholar
  89. 89.
    Hellenbrand W, Claus H, Schink S, Marcus U, Wichmann O, Vogel U (2016) Risk of invasive meningococcal disease in men who have sex with men: lessons learned from an outbreak in Germany, 2012–2013. PLoS ONE 11(8):e160126PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Folaranmi TA, Kretz CB, Kamiya H, MacNeil JR, Whaley MJ, Blain A et al (2017) Increased risk for meningococcal disease among men who have sex with men in the United States, 2012–2015. Clin Infect Dis 65(5):756–763PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Dubois C, Liegeon AL, Fabbro C, Truchetet F (2017) Neisseria meningitidis urethritis: two case reports. Ann Dermatol Venereol 144(10):621–623PubMedCrossRefGoogle Scholar
  92. 92.
    Gutierrez-Fernandez J, Medina V, Hidalgo-Tenorio C, Abad R (2017) Two cases of Neisseria meningitidis proctitis in HIV-positive men who have sex with men. Emerging Infect Dis 23(3):542–543PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Siberry GK, Warshaw MG, Williams PL, Spector SA, Decker MD, Jean-Philippe P et al (2012) Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children. Pediatr Infect Dis J 31(1):47–52PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Lujan-Zilbermann J, Warshaw MG, Williams PL, Spector SA, Decker MD, Abzug MJ et al (2012) Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus. J Pediatr 161(4):676–681.e2PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Warshaw MG, Siberry GK, Williams P, Decker MD, Jean-Philippe P, Lujan-Zilbermann J (2017) Immunogenicity of a booster dose of quadrivalent meningococcal conjugate vaccine in previously immunized HIV-infected children and youth. J Pediatric Infect Dis Soc 6(3):e69–e74PubMedCrossRefGoogle Scholar
  96. 96.
    Yin Z, Rice BD, Waight P, Miller E, George R, Brown AE et al (2012) Invasive pneumococcal disease among HIV-positive individuals, 2000–2009. AIDS 26(1):87–94PubMedCrossRefGoogle Scholar
  97. 97.
    Jallow S, Madhi SA (2017) Pneumococcal conjugate vaccine in HIV-infected and HIV-exposed, uninfected children. Expert Rev Vaccines 16(5):453–465PubMedCrossRefGoogle Scholar
  98. 98.
    Nunes MC, von Gottberg A, de Gouveia L, Cohen C, Moore DP, Klugman KP et al (2011) The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. AIDS 25(4):453–462PubMedCrossRefGoogle Scholar
  99. 99.
    von Mollendorf C, von Gottberg A, Tempia S, Meiring S, de Gouveia L, Quan V et al (2015) Increased risk for and mortality from invasive pneumococcal disease in HIV-exposed but uninfected infants aged 〈1 year in South Africa, 2009–2013. Clin Infect Dis 60(9):1346–1356CrossRefGoogle Scholar
  100. 100.
    Lesourd A, Leporrier J, Delbos V, Unal G, Honore P, Etienne M et al (2016) Antiretroviral Therapy as Prevention of ... Pneumococcal Infections? Open Forum Infect Dis 3(4):ofw228PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Feldman C, Anderson R, Rossouw T (2017) HIV-related pneumococcal disease prevention in adults. Expert Rev Respir Med 11(3):181–199PubMedCrossRefGoogle Scholar
  102. 102.
    French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H et al (2010) A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 362(9):812–822PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Penaranda M, Falco V, Payeras A, Jordano Q, Curran A, Pareja A et al (2007) Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study. Clin Infect Dis 45(7):e82–7PubMedCrossRefGoogle Scholar
  104. 104.
    Teshale EH, Hanson D, Flannery B, Phares C, Wolfe M, Schuchat A et al (2008) Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998–2003. Vaccine 26(46):5830–5834PubMedCrossRefGoogle Scholar
  105. 105.
    Iyer AS, Leggat DJ, Ohtola JA, Duggan JM, Georgescu CA, Al Rizaiza AA et al (2015) Response to Pneumococcal Polysaccharide Vaccination in HIV-Positive Individuals on Long Term Highly Active Antiretroviral Therapy. J AIDS Clin Res.  https://doi.org/10.4172/2155-6113.1000419 CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    Leggat DJ, Iyer AS, Ohtola JA, Kommoori S, Duggan JM, Georgescu CA et al (2015) Response to pneumococcal polysaccharide vaccination in newly diagnosed HIV-positive individuals. J AIDS Clin Res.  https://doi.org/10.4172/2155-6113.1000419 CrossRefPubMedPubMedCentralGoogle Scholar
  107. 107.
    Levin MJ, Song LY, Fenton T, Nachman S, Patterson J, Walker R et al (2008) Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine 26(33):4210–4217PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB (2017) Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older—United States, 2017. Mmwr Morb Mortal Wkly Rep 66(5):136–138PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Robert Koch-Institut (2017) Stellungnahme der Ständigen Impfkommission (STIKO) am RKI: Fachliche Anwendungshinweise zur Masern-Postexpositionsprophylaxe bei Risikopersonen. Epidemiol Bull 2/2017:17–25Google Scholar
  110. 110.
    Taweesith W, Puthanakit T, Kowitdamrong E, Bunupuradah T, Wongngam W, Phasomsap C et al (2011) The immunogenicity and safety of live attenuated varicella-zoster virus vaccine in human immunodeficiency virus-infected children. Pediatr Infect Dis J 30(4):320–324PubMedCrossRefGoogle Scholar
  111. 111.
    Weinberg A, Levin MJ, Macgregor RR (2010) Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults. Hum Vaccin 6(4):318–321PubMedCrossRefGoogle Scholar
  112. 112.
    Robert Koch-Institut (2013) Mitteilung der Ständigen Impfkommission (STIKO) am RKI. Empfehlung und wissenschaftliche Begründung der Empfehlung zur Rotavirus-Standardimpfung von Säuglingen. Epidemiologisches Bulletin, 35/2013Google Scholar
  113. 113.
    Lewis DJ, Gilks CF, Ojoo S, Castello-Branco LR, Dougan G, Evans MR et al (1994) Immune response following oral administration of cholera toxin B subunit to HIV-1-infected UK and Kenyan subjects. AIDS 8(6):779–785PubMedCrossRefGoogle Scholar
  114. 114.
    Westrop SJ, Moyle G, Jackson A, Nelson M, Mandalia S, Imami N (2012) CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection. Mol Med 18:1240–1248PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Robert Koch-Institut (2017) FSME: Risikogebiete in Deutschland (Stand: April 2017). Epidemiologisches Bulletin. http://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2017/17/Art_01.html . Zugegriffen: 19. Juni 2018
  116. 116.
    Pfizer. Fachinformation FSME-Immun für Erwachsene. 2017. Google Scholar
  117. 117.
    GSK. Fachinformation Encepur Erwachsene. 2017. Google Scholar
  118. 118.
    Barte H, Horvath TH, Rutherford GW (2014) Yellow fever vaccine for patients with HIV infection. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD010929.pub2 PubMedCrossRefGoogle Scholar
  119. 119.
    Kengsakul K, Sathirapongsasuti K, Punyagupta S (2002) Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 85(1):131–134PubMedGoogle Scholar
  120. 120.
    Avelino-Silva VI, Miyaji KT, Hunt PW, Huang Y, Simoes M, Lima SB et al (2016) CD4/CD8 ratio and KT ratio predict yellow fever vaccine Immunogenicity in HIV-infected patients. Plos Negl Trop Dis 10(12):e5219PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Veit O, Niedrig M, Chapuis-Taillard C, Cavassini M, Mossdorf E, Schmid P et al (2009) Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 48(5):659–666PubMedCrossRefGoogle Scholar
  122. 122.
    Veit O, Domingo C, Niedrig M, Staehelin C, Sonderegger B, Delphine H et al (2017) Long-term immune response to yellow fever vaccination in HIV-infected individuals depends on HIV-RNA suppression status: Implications for vaccination schedule. Clin Infect Dis.  https://doi.org/10.1093/cid/cix960 CrossRefGoogle Scholar
  123. 123.
    Deutsche Tropenmedizinische Gesellschaft, DTG (2017) Reisemedizinische Empfehlungen. http://dtg.org/empfehlungen-und-leitlinien/empfehlungen/impfungen.html . Zugegriffen: 19. Juni 2018 Google Scholar
  124. 124.
    Rojanasuphot S, Shaffer N, Chotpitayasunondh T, Phumiamorn S, Mock P, Chearskul S et al (1998) Response to JE vaccine among HIV-infected children, Bangkok, Thailand. Southeast Asian J Trop Med Public Health 29(3):443–450PubMedGoogle Scholar
  125. 125.
    Pancharoen C, Thisyakorn U, Tantawichien T, Jaijaroensup W, Khawplod P, Wilde H (2001) Failure of pre- and postexposure rabies vaccinations in a child infected with HIV. Scand J Infect Dis 33(5):390–391PubMedCrossRefGoogle Scholar
  126. 126.
    Ni JD, Xiong YZ, Wang XJ, Xiu LC (2013) Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard dose vaccination: a meta-analysis? Int J Std Aids 24(2):117–122PubMedCrossRefGoogle Scholar
  127. 127.
    MacNeil JR, Rubin LG, Patton M, Ortega-Sanchez IR, Martin SW (2016) Recommendations for use of meningococcal conjugate vaccines in HIV-infected persons—advisory committee on immunization practices, 2016. MMWR Morb Mortal Wkly Rep 65(43):1189–1194PubMedCrossRefGoogle Scholar
  128. 128.
    Slayter KL, Singer J, Lee TC, Kayhty H, Schlech WF (2013) Immunization against pneumococcal disease in HIV-infected patients: conjugate versus polysaccharide vaccine before or after reconstitution of the immune system (CTN-147). Int J Std Aids 24(3):227–231PubMedCrossRefGoogle Scholar
  129. 129.
    Sogaard OS, Schonheyder HC, Bukh AR, Harboe ZB, Rasmussen TA, Ostergaard L et al (2010) Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy. AIDS 24(9):1315–1322PubMedCrossRefGoogle Scholar
  130. 130.
    Stermole BM, Grandits GA, Roediger MP, Clark BM, Ganesan A, Weintrob AC et al (2011) Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults. Vaccine 29(16):2874–2880PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Schwarze-Zander C, Draenert R, Lehmann C, Stecher M, Boesecke C, Sammet S et al (2017) Measles, mumps, rubella and VZV: importance of serological testing of vaccine-preventable diseases in young adults living with HIV in Germany. Epidemiol Infect 145(2):236–244PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Personalised recommendations